RxDoctor Payments DataLook up a doctor →

Eugenia Girda, MD

Gynecologic Oncology · New Brunswick, NJNPI 1497032106

Payments from drug & device makers

$4,204,140in general payments, 2019–2025

Across 243 payments — averaging $17,301 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$2M
  • Merck$1.6M
  • Astellas Pharma Global Development$175K
  • Astrazeneca UK Limited$164K
  • Genentech, Inc.$110K
  • Exelixis Inc.$107K
  • plus $58K from 7 others
$7,117in research payments, 2019–2025

Across 22 payments — averaging $323.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$6K
  • F. Hoffmann-la Roche AG$1K

General payments by program year

19
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,204,140 in reported general payments places this provider in the 95th percentile of 45 gynecologic oncology providers in New Jersey.

See all gynecologic oncology providers in New Jersey

Medicare billing

Part B allowed, 2024
$44,493
Medicare patients
86
Services billed
270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in New Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →